Biovica International signed a collaboration agreement for DiviTum® TKa in Spain and Portugal with the Palex Group, a leading hospital equipment supplier with a proven track record in taking oncology tests and surgical instruments to market in southern Europe. The collaboration aims at making the test available to more than 8,000 cases of metastatic breast cancer patients diagnosed each year in Spain and Portugal. Palex will lead the introduction and adoption of DiviTum TKa, focusing efforts on generating a high level of awareness and knowledge among breast oncologists and other relevant decision-makers and incorporating the test into clinical guidelines, thanks to its differential value for professionals and patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.706 SEK | +6.36% | -22.81% | -33.88% |
Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.88% | 13.08M | |
-20.45% | 10.82B | |
+43.17% | 3.25B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
-29.81% | 1.48B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
-46.94% | 377M |
- Stock Market
- Equities
- BIOVIC B Stock
- News Biovica International AB
- Biovica International Signs Agreement with Palex Group